Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Vascular Permeability Factor, Etc.); Or Binds Serum Protein, Plasma Protein, Fibrin, Or Enzyme Patents (Class 424/158.1)
-
Patent number: 9540449Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (PCSK9) with greater affinity at neutral pH than at acidic pH. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit pH-dependent binding properties. For example, the present invention includes anti-PCSK9 antibodies which possess one or more histidine substitutions in one or more complementarity determining regions. The antibodies of the invention, with pH-dependent binding properties, remain in circulation and exhibit cholesterol lowering activity for prolonged periods of time in animal subjects as compared to anti-PCSK9 antibodies that do not exhibit pH-dependent binding properties.Type: GrantFiled: August 12, 2013Date of Patent: January 10, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: George D. Yancopoulos, Nicholas J. Papadopoulos, Andrew J. Murphy, Neil Stahl
-
Kit for monitoring immune status after transplant and method for monitoring immune status using same
Patent number: 9448229Abstract: The present invention relates to a method and a kit for monitoring an immune status after transplant. The kit for monitoring an immune status after transplant and the method for monitoring an immune status of an individual after transplant as provided in the present invention make it easy and accurate to determine an immune status in the individual after transplant and thus have an effect of reducing overuse of an immunosuppressive agent prescribed after transplant and also have an effect of conveniently managing an immune status of each patient.Type: GrantFiled: November 7, 2014Date of Patent: September 20, 2016Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Chul-Woo Yang, Jong-Young Choi, Joo-Yeon Jhun, Hee-Yeon Kim, Jae-Kyeong Byun, Ye-Been Yim, Byung-Ha Chung, Kyoung-Woon Kim -
Patent number: 9365646Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.Type: GrantFiled: December 3, 2013Date of Patent: June 14, 2016Assignee: NOVARTIS AGInventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
-
Patent number: 9358288Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.Type: GrantFiled: November 10, 2014Date of Patent: June 7, 2016Assignee: Yeda Research and Development Co., Ltd.Inventors: Michael Sela, Yosef Yarden, Bilha Schechter, Tsipi Ben-Kasus
-
Patent number: 9339484Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.Type: GrantFiled: February 16, 2013Date of Patent: May 17, 2016Assignee: CELLIX BIO PRIVATE LIMITEDInventor: Mahesh Kandula
-
Patent number: 9321773Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.Type: GrantFiled: March 20, 2014Date of Patent: April 26, 2016Assignee: Respivert, Ltd.Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
-
Patent number: 9308275Abstract: The preset invention provides a method of increasing the effect of an activated-potentiated form of an antibody to an endogenous biological molecule by combining said endogenous biological molecule with an activated-potentiated form of an antibody to endothelial NO-synthase. The present invention also provides a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to an endogenous biological molecule, and b) an activated-potentiated form of an antibody to NO synthase.Type: GrantFiled: July 15, 2011Date of Patent: April 12, 2016Inventor: Oleg Iliich Epshtein
-
Patent number: 9220781Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: July 14, 2015Date of Patent: December 29, 2015Assignee: ABBVIE BIOTECHNOLOGY LTDInventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 9212222Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.Type: GrantFiled: November 22, 2011Date of Patent: December 15, 2015Assignee: RINAT NEUROSCIENCE CORP.Inventors: Jaume Pons, Arnon Rosenthal
-
Patent number: 9193801Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.Type: GrantFiled: June 30, 2014Date of Patent: November 24, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Scott M. Walsh, Daniel B. Dix
-
Patent number: 9163083Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.Type: GrantFiled: December 12, 2013Date of Patent: October 20, 2015Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas, Gopalan Raghunathan
-
Patent number: 9121858Abstract: The present relates to a method for detecting cardiac remodeling in a subject without clinical signs of heart failure comprising determining the level of the NGAL-MMP9 complex in a blood sample obtained from the patient.Type: GrantFiled: October 12, 2012Date of Patent: September 1, 2015Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite de Lorraine, Centre Hospaitalier et de Nancy (CHU), Universite Paris DescartesInventors: Frederic Jaisser, Patrick Rossignol, Faiez Zannad
-
Publication number: 20150147340Abstract: Described herein are methods and medicaments useful for treating peritoneal carcinomatosis by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods for prognosing individuals with perinoteal carcinomatosis are also provided. In one aspect, the present invention provides a method of treating a subject with peritoneal carcinomatosis, the method comprises the administration to the subject of an effective amount ohm anti-connective tissue growth factor (CTGF) agent, thereby treating the peritoneal carcinomatosis. In some embodiments, the peritoneal carcinomatosis results from a cancer selected from the group consisting of gall bladder cancer, bile duct cancer, liver cancer, colon cancer, cancer of the appendix, ovarian cancer, fallopian tube cancer, bladder cancer, pancreatic cancer, mesothelioma, rectal cancer, small bowel cancer and stomach cancer. In particular embodiments, the cancer is ovarian cancer.Type: ApplicationFiled: March 12, 2013Publication date: May 28, 2015Inventors: Goli Samimi, Kim Moran-Jones
-
Publication number: 20150147326Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.Type: ApplicationFiled: September 30, 2014Publication date: May 28, 2015Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH, Kinki UniversityInventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
-
Publication number: 20150147335Abstract: The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treating hidradenitis suppurativa in a subject.Type: ApplicationFiled: May 28, 2014Publication date: May 28, 2015Inventors: Martin M. Okun, Thomas C. Harris
-
Publication number: 20150147342Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.Type: ApplicationFiled: February 6, 2015Publication date: May 28, 2015Inventors: Israel Lowy, Gavin Thurston, Christopher Daly
-
Publication number: 20150147341Abstract: There is disclosed is a method of treating a pulmonary disease using a pyrimidinecarboxamide compound, and a pharmaceutical composition suitable for inhalation comprising the pyrimidinecarboxamide compound.Type: ApplicationFiled: January 30, 2015Publication date: May 28, 2015Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
-
Publication number: 20150140005Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.Type: ApplicationFiled: May 17, 2013Publication date: May 21, 2015Inventors: Keith R. Walley, John H. Boyd, James A. Russell
-
Publication number: 20150140010Abstract: The present invention relates to methods for diagnosing and treating focal segmental glomerulosclerosis. More particularly, the present invention relates to a method for determining whether a subject is at risk of having or developing a focal segmental glomerulosclerosis (FSGS) comprising the step consisting of determining the level of calcium/calmodulin-dependent serine protein kinase (CASK) in a blood sample obtained from the subject. The present invention also relates to an agent effective to inhibit the binding of CASK to hCD98 present on the surface of podocytes for use in the prevention or treatment of focal segmental glomerulosclerosis (FSGS) in a subject in need thereof.Type: ApplicationFiled: May 22, 2013Publication date: May 21, 2015Applicants: INSERM 9INSTITUT NATIONAL DE LA SANTE ET DE LA R- ECHERCHE MEDICALE), UNIVERSITE PARIS-SUD XI, ASSISTANCE PUBLIQUE-HOPITAUX DE PARISInventors: Antoine Durrbach, Hanz Lorenzo, Severine Beaudreuil
-
Publication number: 20150139909Abstract: The present invention relates to the field of osteoarthritis. More specifically, the present invention provides compositions and methods useful for treating or preventing osteoarthritis. In one embodiment, a method for treating or preventing osteoarthritis in a patient comprises the step of administering to the patient a therapeutically effective amount of a transforming growth factor beta (TGF-beta) inhibitor.Type: ApplicationFiled: May 1, 2013Publication date: May 21, 2015Inventor: Xu Cao
-
Publication number: 20150140009Abstract: The invention provides methods for the treatment of radiation exposure featuring agents that interfere with the expression, production, release, accumulation, or activity of a TNF?, IL6, EGF, IL1-alpha, IL1-beta, G-CSF, MCP-1, MIP-1, SCF, or RANTES receptor; or a TNF-?, IL6, EGF, IL1-alpha, IL1-beta, G-CSF, MCP-1, MIP-1, SCF, or RANTES peptide or fragment thereof.Type: ApplicationFiled: August 19, 2014Publication date: May 21, 2015Inventor: David A. Goukassian
-
Publication number: 20150139983Abstract: The invention provides pharmaceutical compositions for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several blocking agent(s) of Bone Morphogenic Protein (BMP) signaling. The invention further provides methods of treatment of neuroinflammatory or neurodegenerative diseases comprising administering to a patient in need thereof the pharmaceutical compositions of the invention.Type: ApplicationFiled: June 12, 2013Publication date: May 21, 2015Inventors: Arnon Karni, Yifat Amir Levi, Nataly Urshanski, Karin Bernadet Fainberg
-
Publication number: 20150140012Abstract: The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.Type: ApplicationFiled: November 18, 2014Publication date: May 21, 2015Applicant: Nuvo Research AGInventors: Mathias Brosz, Friedrich-Wilhelm Kuhne, Klaus Blaszkiewitz, Thomas Isensee
-
Publication number: 20150140011Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).Type: ApplicationFiled: May 23, 2013Publication date: May 21, 2015Applicant: ARGEN-X B.V.Inventors: Christophe Blanchetot, Johannes De Haard, Torsten Dreier, Natalie De Jonge, Paul Sebastian Van Der Woning, Nicolas Ongenae
-
Publication number: 20150140013Abstract: Provided herein are methods and compositions related to modulation of the rate of asymmetric proliferation of cancer cells. In some embodiments, the methods described herein relate to the treatment of cancer, at least in part, via the modulation of the rate of asymmetric proliferation of cancer cells.Type: ApplicationFiled: January 23, 2015Publication date: May 21, 2015Applicant: THE GENERAL HOSPITAL CORPORATIONInventor: Sridhar RAMASWAMY
-
Patent number: 9034333Abstract: A novel method for validating the utility of a drug in the treatment of inflammatory and cardiovascular diseases is described.Type: GrantFiled: August 29, 2011Date of Patent: May 19, 2015Assignee: University of ZurichInventors: Chad Brokopp, Simon Hoerstrup
-
Publication number: 20150132304Abstract: NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.Type: ApplicationFiled: November 5, 2014Publication date: May 14, 2015Inventors: John A. Latham, Ethan W. Ojala, Jeffrey T.L. Smith, Benjamin H. Dutzar, Leon F. Garcia-Martinez
-
Publication number: 20150132320Abstract: The present invention is directed to modified antibodies, including anti-TNF? antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The invention further provides methods of producing and using such antibodies.Type: ApplicationFiled: December 15, 2014Publication date: May 14, 2015Inventors: Chris M. Chumsae, Zehra Kaymakcalan
-
Publication number: 20150132294Abstract: The present invention relates to compositions and methods for characterizing, regulating, diagnosing, and treating cancer. For example, the present invention provides compositions and methods for inhibiting tumorigenesis of certain classes of cancer cells, including breast cancer cells and preventing metastasis. The present invention also provides systems and methods for identifying compounds that regulate tumorigenesis.Type: ApplicationFiled: November 6, 2014Publication date: May 14, 2015Inventors: Michael F. Clarke, Muhammad Al-Hajj
-
Publication number: 20150132319Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: ApplicationFiled: March 6, 2013Publication date: May 14, 2015Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Patent number: 9028817Abstract: The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.Type: GrantFiled: October 25, 2010Date of Patent: May 12, 2015Assignee: Glaxo Group LimitedInventors: Inusha De Silva, Armin Sepp, Adriaan Allart Stoop
-
Publication number: 20150125470Abstract: Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: March 29, 2013Publication date: May 7, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Jun Hasegawa
-
Publication number: 20150125471Abstract: The present invention relates to a compound which inhibits the binding of activin B to ALK3 receptor or a compound which is an inhibitor of activin B expression or ALK3 receptor expression for use in the treatment of anemia of inflammation. The invention also relates to a method for diagnosis anemia of inflammation in a patient comprising: determining the expression level of Activin B in a sample obtained from said patient; and comparing said expression level to a threshold value.Type: ApplicationFiled: May 3, 2013Publication date: May 7, 2015Inventors: Marie-Paule Roth, Hélène Coppin
-
Publication number: 20150125469Abstract: Compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states are disclosed. In some methods, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain methods, the different states of cancer stem cells are distinguished based on markers CD44+CD24?, EpCam?CD49P+(for EMT cancers stem cells), ALDH+ and EPCam+CD49r? (for MET cancers stem cells), and CD44+CD24?ALDH+ (for EMT-MET cancer stem cells). In particular methods, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).Type: ApplicationFiled: February 8, 2013Publication date: May 7, 2015Inventors: Suling Liu, Max S. Wicha
-
Patent number: 9023355Abstract: Compositions and methods are disclosed herein for treating or reducing the symptoms of a renal disease, such as focal segmental glomerulosclerosis (FSGS), hypertensive end-stage kidney disease (ESKD), and HIV-associated nephropathy (a distinct form of FSGS, also termed collapsing glomerulopathy). The compositions include the common variant of APOL1 and fragments thereof, as well as antibodies and fragments thereof that bind and neutralize pathogenic APOL1, nucleic acid molecules that encode the common variant of APOL1 and fragments thereof, and other compounds that bind and neutralize pathogenic APOL1. The methods of the invention include administering one or more of the compositions of the invention to a subject having or at risk of developing renal disease.Type: GrantFiled: February 24, 2012Date of Patent: May 5, 2015Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: David J. Friedman, Martin R. Pollak
-
Patent number: 9023995Abstract: The present invention relates to anti-interleukin-36R (anti-IL-36R) binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: November 14, 2012Date of Patent: May 5, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Su-Ellen Brown, Keith Canada, Lukasz Chlewicki, Michael Howell, Detlev Mennerich, Joseph Robert Woska, Jr.
-
Publication number: 20150118156Abstract: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.Type: ApplicationFiled: December 23, 2014Publication date: April 30, 2015Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
-
Publication number: 20150118226Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.Type: ApplicationFiled: December 31, 2014Publication date: April 30, 2015Inventors: David J. King, Peter Bowers, Robert A. Horlick, Tamlyn Yee Neben
-
Publication number: 20150118248Abstract: The application describes a method of screening for breast cancer by testing fro the amount of HAGE (Helicase antigen) in a sample of breast tissue. Methods of prognosis of samples of breast cancer tumours are also provided. HAGE+ ER? (estrogen receptor-) cancers are indicated as being amenable to chemotherapy. Methods of treating breast cancers with HAGE-specific CTA antigen or HAGE-specific antibodies are also provided.Type: ApplicationFiled: March 27, 2013Publication date: April 30, 2015Inventors: Adam Linley, Morgan Mathieu, Stephanie Mcardle, Chungui Lu, Robert Rees
-
Publication number: 20150118186Abstract: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).Type: ApplicationFiled: January 5, 2015Publication date: April 30, 2015Inventors: Jordi BACH TAÑA, Lluis Miquel PAGES SANTACANA, Joan TALTAVULL MOLL, Paul Robert EASTWOOD, Jacob GONZALEZ RODRIGUES, Victor GIULIO MATASSA
-
Publication number: 20150118249Abstract: The present invention relates to stable, aqueous antibody formulations. In some embodiments, the stable, aqueous formulations comprise about 2 mg/mL to about 100 mg/mL of an anti-IL5R antibody, and about 0.002% to about 0.01% polysorbate-20. Also provided are methods of making and methods of using such antibody formulations.Type: ApplicationFiled: October 23, 2014Publication date: April 30, 2015Inventors: William Leach, Rachael Lewus, James McGivney, Kelcy Newell, Kevin Douglas Stewart
-
Patent number: 9017684Abstract: Methods that entail detection of an epiregulin (EREG) protein for cancer diagnosis are disclosed. In colon cancer, lung adenocarcinoma, pancreatic cancer, stomach cancer, and kidney cancer, the gene and protein expressions of EREG were frequently found to be elevated. Antibodies that recognize an EREG protein are used for diagnosing or treating cancer in the present invention. Pharmaceutical compositions, cell proliferation inhibitors, and anticancer agents containing an EREG-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in EREG-expressing cells and methods of suppressing the proliferation of EREG-expressing cells by contacting the EREG-expressing cells with EREG-binding antibodies are also disclosed.Type: GrantFiled: October 12, 2007Date of Patent: April 28, 2015Assignees: Chugai Seiyaku Kabushiki Kaisha, The University of TokyoInventors: Hiroyuki Aburatani, Hirotaka Ito, Kenji Yoshida
-
Patent number: 9017686Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies.Type: GrantFiled: February 18, 2011Date of Patent: April 28, 2015Assignee: Genentech, Inc.Inventors: Jenny M. Bostrom, Germaine Fuh
-
Patent number: 9017685Abstract: The present disclosure demonstrates for the first time that Th-17 cells are the product of a distinct CD4+ T cell lineage with unique developmental and functional characteristics. The developmental signals required for Th-17 commitment and development are also described. As a result, the teachings of the present disclosure provide a basis for understanding the developmental pathway of Th-17 cells and offer novel avenues to modulate (stimulate or inhibit) this developmental program and offer new methods for the treatment and prevention of disease states and conditions related to aberrant activity of Th-17 cells.Type: GrantFiled: October 16, 2009Date of Patent: April 28, 2015Assignee: The UAB Research FoundationInventors: Casey T. Weaver, Paul R. Mangan, Laurie E. Harrington
-
Patent number: 9017687Abstract: The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.Type: GrantFiled: November 13, 2013Date of Patent: April 28, 2015Assignee: AbbVie, Inc.Inventors: Chen Wang, Germano Coppola, Chris Chumsae
-
Patent number: 9017674Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.Type: GrantFiled: April 30, 2012Date of Patent: April 28, 2015Assignee: KaloBios Pharmaceuticals, Inc.Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey Yarranton
-
Publication number: 20150110803Abstract: The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.Type: ApplicationFiled: November 13, 2013Publication date: April 23, 2015Inventors: Chen Wang, Germano Coppola, Chris Chumsae
-
Publication number: 20150110787Abstract: A polypeptide, antagonist, and antibody that specifically bind to and inhibit VEGF-C and uses thereof in a method of inhibiting angiogenesis and a method of preventing, treating, and/or diagnosing a disease associated with activation and/or overexpression of VEGF-C, using the antibody, and a method of detecting the presence of VEGF-C in a sample.Type: ApplicationFiled: October 20, 2014Publication date: April 23, 2015Inventors: Seok Kyun KIM, Sang Yeul HAN, Kwang Hoon LEE, Kyung Eun KIM
-
Publication number: 20150110802Abstract: Methods are provided for producing a plurality of antibody species in a single animal, comprising delivering a plurality of antigen species to a single animal, where each antigen species is delivered to the animal at an anatomically distinct location. Also provided are methods for generating an immune response in an animal, where each antigen species is delivered to the animal at an anatomically distinct location, under conditions in which the animal produces a plurality of antibody species, where each antibody species specifically binds to a different antigen species among the plurality of antigen species.Type: ApplicationFiled: February 26, 2013Publication date: April 23, 2015Applicant: Medlmmune, LLCInventors: Partha S. Chowdhury, Chew-Shun Chang
-
Publication number: 20150110805Abstract: Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases. In addition, the present invention relates to the determination that regulator cells are cycling in degenerative diseases. Based on these realizations, the present invention provides methods for treating conditions such as autoimmune diseases, degenerative diseases, and graft-versus-host disease. The present invention also relates to methods of determining when therapy should be administered to a patient.Type: ApplicationFiled: December 22, 2014Publication date: April 23, 2015Inventors: Martin Leonard Ashdown, Luisa Maria Ashdown